Interrogating cutaneous T-cell lymphoma tissues with 56 markers using CODEX imaging

from Nolan's Lab, Stanford University, 16th June 2021

Darci Phillips and colleagues have developed a 56-marker CODEX antibody panel comprised of structural, tumor, and immune cell markers, including eight immunoregulatory proteins that are approved or currently undergoing clinical trials as immunotherapy targets.

The complex interactions between tumor, immune, and other cells in the tumor microenvironment (TME) affect the efficacy of cancer immunotherapy. The Nolan Lab from Stanford University has developed a multiplexed tissue imaging platform called CO-Detection by indEXing (CODEX) that can detect up to 60 markers simultaneously in the same tissue sections at the single-cell level. They recently used the technology to develop a 56-marker panel and use it to characterize the tumor samples from eight cutaneous T-cell lymphoma (CTCL) patients. The marker panel provides a blueprint to study tumor immunology, tissue architecture, and mechanisms of immunotherapeutic targets.


Multiplexed IHC/IF @ JEDI

from Joe Yeong's Lab, 13th Jan 2020

mIHC/IF images of colorectal (left), lung (middle) and ovarian (right) cancer tissues stained with standard immune marker panel: DNA (blue), PD-L1 (cyan), CD3 (green), CD68 (yellow), FOXP3 (orange), CD8 (magenta) and CK (red).

Standard reference images are important to standardize and benchmark different staining and imaging protocols. JEDI is a multi-disciplinary taskforce with more than 30 members across the world, working closely with the Society of Immunotherapy for Cancer (SITC) and World Immunotherapy Council (WIC) to help the standardization and translation of multiplex IHC/IF technologies for clinical research and cancer immunotherapy application.

New ImmunoAtlas Reports

Simultaneous PD-L1 testing in cancers using mIHC/IF

from Joe Yeong's Lab, 29th Nov 2020

A study based on simultaneous detection and quantification of three different programmed death-ligand 1 (PD-L1) antibodies found moderate-to-strong correlations between their staining levels in conventional immunohistochemistry (IHC) and multiplex immunohistochemistry/ immunofluorescence (mIHC/IF).

first story thumbnail a
Simultaneous staining of EpCAM antibody (red) and three PD-L1 antibodies: 22C3 (magenta), SP142 (yellow) and SP263 (green) in cancer tissues.

CD38, a possible predictive marker of immunotherapy responsiveness in hepatocellular carcinoma

from Joe Yeong's Lab, 26th Nov 2020

A study showed that quantifications of CD38+ cells and CD38+CD68+ macrophages can more accurately predict immune-checkpoint-blockade responsiveness than quantifications based on programmed death-ligand 1 (PD-L1) or CD8+ T cells only.

second story thumbnail b
HCC tissues stained with CD38 (yellow), PD-L1 (green), macrophage marker CD68 (red) and cell nuclei (blue).

Whole-slide IHC and mIHC/IF imaging of the same tissue section

from Joe Yeong's Lab, 7th Dec 2020

A new study performed whole-slide multiplexed immunohistochemistry and immunofluorescence (mIHC/IF) and hematoxylin and eosin (H&E) staining and imaging on the same human tonsil section. This is a promising method to simultaneously and spatially quantify overall tissue morphology and various molecular phenotypes of cancer and immune cells in the tumor microenvironments.

mIHC/IF thumbnail
H&E thumbnail
Whole slide mIHC/IF image (left) of human tonsil tissue stained with DNA (blue), CD20 (cyan), CD45 (green), CD3 (magenta) and CD68 (orange), and its corresponding H&E staining (right).